The U.S. Patent and Trademark Office issued a patent to Subtle Medical for its software application SubtleGAD that aims to significantly reduce gadolinium dosage during imaging procedures.
The company was issued U.S. patent No. 10,997,716 for SubtleGAD, which is said to reduce the gadolinium dosage by 90% while maintaining high-quality diagnostic MRI images. Currently in the investigational phase, the software uses proprietary deep-learning algorithms to achieve equivalent diagnostic image quality using only 10% of the gadolinium contrast dose.
Subtle Medical claims that SubtleGAD can reduce gadolinium dosage by 90%. Image courtesy of Subtle Medical.
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)
.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)
